Mainz Biomed B.V.
MYNZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 2.14 | -12.69 | -0.08 |
| FCF Yield | -414.68% | -3.16% | -0.38% | -0.11% |
| EV / EBITDA | -0.06 | -30.15 | -155.80 | -265.11 |
| Quality | ||||
| ROIC | -192.86% | -233.79% | -152.64% | -112.31% |
| Gross Margin | 64.31% | 56.91% | 34.38% | 30.77% |
| Cash Conversion Ratio | 0.79 | 0.83 | 0.56 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.05% | 15.75% | 2.39% | 27.07% |
| Free Cash Flow Growth | 27.24% | -54.51% | -376.61% | -576.61% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | -0.01 | 0.54 | 0.55 |
| Interest Coverage | -17.39 | -32.91 | -91.40 | -28.67 |
| Efficiency | ||||
| Inventory Turnover | 0.86 | 0.63 | 1.98 | 0.00 |
| Cash Conversion Cycle | -920.79 | -1,475.87 | -1,036.58 | -748.97 |